US bill seeks to improve use of accelerated approval pathway for ultra-rare drugs
This article was originally published in SRA
Executive Summary
US lawmakers have introduced a bill designed to improve access to the Food and Drug Administration's accelerated approval pathway for medicines designed to treat life-threatening, ultra-rare diseases1,2.